Abstract
Anthracycline/taxane-based primary systemic therapy with or without trastuzumab is the backbone of treatment for patients with stage II–III HER2-positive and triple-receptor-negative breast cancer, respectively. This approach leads to a pathological complete response (no residual invasive cancer in the breast or axilla) in 30–50% of patients.1 The introduction of trastuzumab, and recently dual therapy with trastuzumab and pertuzumab, or trastuzumab and lapatinib, has further improved pathological complete response in patients with HER2-positive breast cancer to around 60%.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
